BRAF mutation + MSI-L/dMMR
|
LUAD
|
BRAF mutation + MSI-L/dMMR
|
LUAD
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
BRAF mutation + MSI-L/dMMR
|
CRC
|
BRAF mutation + MSI-L/dMMR
|
CRC
|
camrelizumab + SHR7390 Sensitive: C3 – Early Trials
|
camrelizumab + SHR7390 Sensitive: C3 – Early Trials
|